Skip to main content
Year archive

Valneva SE — 2022 filings

All 206 regulatory filings released by Valneva SE (VLA) in 2022, sourced directly from the official regulator.

206 Filings
2022 Period
2022 filings (206)
Filing Released Lang
Valneva annonce de nouvelles données de rappel hétérologue pour son vaccin inactivé contre la COVID-19
Regulatory Filings
2022-12-30 French
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
Regulatory Filings
2022-12-30 English
FORM 6-K
Foreign Filer Report
2022-12-23 English
Valneva achève la soumission du dossier de demande d’autorisation de mise sur le marché auprès de la FDA pour son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-12-23 French
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate
Regulatory Filings
2022-12-23 English
Valneva rencontrera des investisseurs lors de la J.P. Morgan Healthcare Conference et du Oddo BHF Forum
Regulatory Filings
2022-12-21 French
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
Report Publication Announcement
2022-12-21 English
FORM 6-K
Foreign Filer Report
2022-12-06 English
Valneva confirme sa journée investisseurs à New York
Regulatory Filings
2022-12-06 French
Valneva Hosts Investor Day in New York City
Investor Presentation
2022-12-06 English
VALNEVA - Déclaration d’actions et de droits de vote : 30 novembre 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-05 French
VALNEVA - Declaration of shares and voting rights: November 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-12-05 English
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
Earnings Release FY 2022
2022-12-05 English
Valneva annonce des données positives à douze mois sur la persistance des anticorps avec son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-12-05 French
FORM 6-K
Foreign Filer Report
2022-12-01 English
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate
Regulatory Filings
2022-12-01 English
Valneva et Pfizer annoncent des données à six mois sur la persistance des anticorps chez les enfants et les adultes avec leur candidat vaccin contre la maladie de Lyme
Earnings Release FY 2022
2022-12-01 French
Valneva organise une journée investisseurs à New York
Report Publication Announcement
2022-11-29 French
Valneva to Host Investor Day in New York City
Report Publication Announcement
2022-11-29 English
FORM 6-K
Foreign Filer Report
2022-11-17 English
Valneva annonce la nomination de Dipal Patel en tant que Chief Commercial Officer
Board/Management Information
2022-11-17 French
Valneva Appoints Dipal Patel as Chief Commercial Officer
Board/Management Information
2022-11-17 English
SC 13D
Major Shareholding Notification
2022-11-16 English
6-K
Foreign Filer Report
2022-11-10 English
Valneva publie ses résultats financiers pour les neuf premiers mois de l’exercice 2022 et fait un point sur ses activités
Interim / Quarterly Report 9M 2022
2022-11-10 French
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
Interim / Quarterly Report FY 2022
2022-11-10 English
FORM 6-K
Foreign Filer Report
2022-11-08 English
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Regulatory Filings
2022-11-07 English
Valneva fera une présentation et participera à des réunions investisseurs lors de la Jefferies Healthcare Conference de Londres
Report Publication Announcement
2022-11-07 French
VALNEVA - Déclaration d’actions et de droits de vote : 31 octobre 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-04 French
VALNEVA - Declaration of shares and voting rights: October 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-11-04 English
Franchissements de seuils
Major Shareholding Notification
2022-10-13 French
FORM 6-K
Foreign Filer Report
2022-10-11 English
Valneva présentera les résultats de son candidat vaccin à injection unique contre le chikungunya lors de conférences scientifiques de premier plan
Regulatory Filings
2022-10-10 French
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences
Regulatory Filings
2022-10-10 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-10-07 English
VALNEVA - Declaration of shares and voting rights: Interim status at October 4, 2022 (and information at September 30, 2022)
Share Issue/Capital Change
2022-10-07 English
VALNEVA - Déclaration d’actions et de droits de vote : Situation intermédiaire au 4 octobre 2022 (et information au 30 septembre 2022)
Declaration of Voting Results & Voting Rights Announcements
2022-10-07 French
Franchissement de seuils
Major Shareholding Notification
2022-10-07 French
FORM 6-K
Foreign Filer Report
2022-10-06 English
Valneva annonce la réalisation d’une Offre Globale sursouscrite s’élevant à €102,9 millions
Share Issue/Capital Change
2022-10-04 French
Valneva Announces Closing of Upsized €102.9 Million Global Offering
Share Issue/Capital Change
2022-10-04 English
CURRENT REPORT OF FOREIGN ISSUER
Foreign Filer Report
2022-09-30 English
PROSPECTUS
Prospectus
2022-09-30 English
Valneva annonce la fixation du prix de son Offre Globale d’American Depositary Shares et d’actions ordinaires de €102,9 millions
Capital/Financing Update
2022-09-30 French
Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares
Capital/Financing Update
2022-09-30 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2022-09-29 English
PROSPECTUS
Prospectus
2022-09-29 English
Valneva annonce le lancement d’un projet d’offre globale d'environ $40 millions d’American Depositary Shares et d’actions ordinaires
Capital/Financing Update
2022-09-28 French
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares
Share Issue/Capital Change
2022-09-28 English
FORM 6-K
Foreign Filer Report
2022-09-26 English
FORM 6-K
Foreign Filer Report
2022-09-20 English
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
M&A Activity
2022-09-16 English
Valneva et IDT Biologika mettent fin à leur collaboration sur COVID-19 d’un commun accord
Regulatory Filings
2022-09-16 French
FORM 6-K
Foreign Filer Report
2022-09-08 English
Rapport financier semestriel 2022
Interim / Quarterly Report H2 2022
2022-09-08 French
Valneva et VBI Vaccines Annoncent un partenariat pour la commercialisation et la distribution du vaccin PreHevbri® en Europe
Regulatory Filings
2022-09-08 French
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri®
Regulatory Filings
2022-09-08 English
Valneva annonce la publication dans le Lancet Infectious Diseases des résultats de Phase 3 pour son vaccin contre la COVID-19
Environmental & Social Information
2022-09-06 French
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
Regulatory Filings
2022-09-06 English
VALNEVA - Déclaration d’actions et de droits de vote : 31 août 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-05 French
VALNEVA - Declaration of shares and voting rights: August 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-09-05 English
FORM 6-K
Foreign Filer Report
2022-08-29 English
Valneva annonce de nouveaux résultats positifs d’immunogénicité de Phase 3 et les premiers résultats d’utilisation comme rappel hétérologue de son vaccin inactivé et adjuvanté contre la COVID-19, VLA2
Earnings Release Q3 2022
2022-08-29 French
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001
Earnings Release Q3 2022
2022-08-29 English
FORM 6-K
Foreign Filer Report
2022-08-26 English
Valneva confirme les recommandations de l'OMS pour son vaccin inactivé contre la COVID-19
Regulatory Filings
2022-08-23 French
Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
Environmental & Social Information
2022-08-23 English
Regulatory Filings 2022
Regulatory Filings
2022-08-22 English
FORM 6-K
Foreign Filer Report
2022-08-19 English
Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
Regulatory Filings
2022-08-18 English
Valneva débute la soumission progressive du dossier de demande d’autorisation de mise sur le marché auprès de la FDA pour son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-08-18 French
Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense
Regulatory Filings
2022-08-18 English
Valneva fait un point sur son contrat de fourniture d’IXIARO® au département américain de la Défense
Regulatory Filings
2022-08-18 French
Regulatory Filings 2022
Regulatory Filings
2022-08-17 English
Regulatory Filings 2022
Regulatory Filings
2022-08-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2022-08-15 English
Valneva Establishes an At-the-Market (ATM) Program on Nasdaq
Share Issue/Capital Change
2022-08-15 English
Valneva met en place un programme « At-the-Market (ATM) » sur le Nasdaq
Capital/Financing Update
2022-08-15 French
REGISTRATION STATEMENT
Regulatory Filings
2022-08-12 English
AMENDMENT TO FORM 6-K
Foreign Filer Report
2022-08-11 English
CURRENT REPORT OF FOREIGN ISSUER
Foreign Filer Report
2022-08-11 English
Valneva publie ses résultats financiers du premier semestre 2022 et fait un point sur ses activités
Earnings Release H1 2022
2022-08-11 French
Valneva Reports H1 2022 Results and Provides Corporate Updates
Earnings Release H1 2022
2022-08-11 English
FORM 6-K
Foreign Filer Report
2022-08-09 English
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Regulatory Filings
2022-08-08 English
Valneva et Pfizer lancent une étude de Phase 3 pour leur candidat vaccin contre la maladie de Lyme VLA15
Regulatory Filings
2022-08-08 French
VALNEVA - Declaration of shares and voting rights - July 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-04 English
VALNEVA - Déclaration d’actions et de droits de vote - 31 juillet 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-04 French
FORM 6-K
Foreign Filer Report
2022-08-03 English
Valneva confirme l’avenant au contrat d'achat avec la Commission Européenne pour son vaccin inactivé contre la COVID-19
Regulatory Filings
2022-08-01 French
Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine
Regulatory Filings
2022-08-01 English
FORM 6-K
Foreign Filer Report
2022-07-20 English
European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine
Earnings Release FY 2022
2022-07-20 English
La Commission européenne approuve un avenant au contrat d'achat du vaccin inactivé contre la COVID-19 de Valneva
M&A Activity
2022-07-20 French
VALNEVA - Declaration of shares and voting rights - June 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-05 English
VALNEVA - Déclaration d’actions et de droits de vote - 30 juin 2022
Declaration of Voting Results & Voting Rights Announcements
2022-07-05 French
Franchissement de seuil
Major Shareholding Notification
2022-06-30 French
Franchissement de seuils
Major Shareholding Notification
2022-06-30 French
Valneva SE Déclaration d’actions et de droits de vote - Situation intermédiaire au 22 juin 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-27 French
Valneva SE Declaration of shares and voting rights - Interim status at June 22, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-06-27 English
FORM 6-K
Foreign Filer Report
2022-06-24 English
Valneva reçoit une autorisation de mise sur le marché en Europe pour son vaccin inactivé à virus entier contre la COVID-19, VLA2001
Regulatory Filings
2022-06-24 French
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
Regulatory Filings
2022-06-24 English
Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members
AGM Information
2022-06-24 English
Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination de deux nouveaux membres du Conseil de surveillance
Declaration of Voting Results & Voting Rights Announcements
2022-06-24 French
FORM 6-K
Foreign Filer Report
2022-06-23 English
Valneva and Pfizer Announce Closing of Equity Investment
Share Issue/Capital Change
2022-06-23 English
Valneva et Pfizer annoncent la réalisation de l’opération de souscription au capital
Capital/Financing Update
2022-06-23 French
Valneva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Delisting Announcement
2022-06-23 French
Valneva announces resumption of trading of its ordinary shares on Euronext Paris
Delisting Announcement
2022-06-23 English
Valneva reçoit un avis positif du CHMP pour une autorisation de mise sur le marché en Europe de son candidat vaccin inactivé contre la COVID-19
Regulatory Filings
2022-06-23 French
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe
Regulatory Filings
2022-06-23 English
Valneva et Pfizer signent un accord de souscription d’actions et amendent les termes de leur accord de collaboration pour le candidat vaccin contre la maladie de Lyme VLA15
Share Issue/Capital Change
2022-06-20 French
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Share Issue/Capital Change
2022-06-20 English
FORM 6-K
Foreign Filer Report
2022-06-15 English
Valneva Announces Settlement Agreement with the UK Government
Legal Proceedings Report
2022-06-15 English
Valneva conclut un accord de règlement à l’amiable avec le gouvernement britannique
Legal Proceedings Report
2022-06-15 French
FORM 6-K
Foreign Filer Report
2022-06-10 English
Valneva fait un point sur son candidat vaccin européen inactivé à virus entier contre la COVID-19, VLA2001
Regulatory Filings
2022-06-10 French
Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001
Regulatory Filings
2022-06-10 English
FORM 6-K
Foreign Filer Report
2022-06-08 English
Valneva Joins Euronext’s Tech Leaders Index
Regulatory Filings
2022-06-08 English
Valneva entre dans l’indice Euronext Tech Leaders
Regulatory Filings
2022-06-08 French
Valneva fera une présentation sur son candidat vaccin à injection unique contre le chikungunya et tiendra un symposium à la conférence NECTM8
Regulatory Filings
2022-06-07 French
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate, Host Symposium at NECTM8
Regulatory Filings
2022-06-07 English
FORM 6-K
Foreign Filer Report
2022-06-03 English
Valneva fera une présentation et participera à des réunions investisseurs lors de la conférence Jefferies à New York
Investor Presentation
2022-06-03 French
Valneva to Present and Hold Investor Meetings at the Jefferies US Healthcare Conference
Investor Presentation
2022-06-03 English
Valneva annonce la mise à disposition des documents préparatoires aux assemblées d’actionnaires
AGM Information
2022-06-02 French
Valneva Announces the Availability of Documentation for its Shareholder Meetings
AGM Information
2022-06-02 English
Valneva annonce la nomination de Thomas Decker et Michael Pfleiderer à son Conseil scientifique
Board/Management Information
2022-05-31 French
Valneva Appoints Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board
Board/Management Information
2022-05-31 English
FORM 6-K
Foreign Filer Report
2022-05-25 English
Valneva achève avec succès l’essai d’homogénéité des lots cliniques de son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-05-25 French
Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate
Regulatory Filings
2022-05-25 English
FORM 6-K
Foreign Filer Report
2022-05-20 English
L'EMA accepte la soumission du dossier d’autorisation de mise sur le marché du candidat vaccin inactivé contre la COVID-19 de Valneva
Regulatory Filings
2022-05-19 French
EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate
Regulatory Filings
2022-05-19 English
FORM 6-K
Foreign Filer Report
2022-05-16 English
Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement
Legal Proceedings Report
2022-05-16 English
Valneva reçoit de la Commission Européenne un avis d’intention de résiliation de son contrat de fourniture de vaccins contre la COVID-19
Legal Proceedings Report
2022-05-16 French
Les Émirats arabes unis autorisent l’utilisation d’urgence du vaccin inactivé de Valneva contre la COVID-19
Regulatory Filings
2022-05-16 French
Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine
Regulatory Filings
2022-05-16 English
FORM 6-K
Foreign Filer Report
2022-05-05 English
Valneva Reports Q1 2022 Results and Provides Corporate Updates
Earnings Release Q1 2022
2022-05-05 English
Valneva publie ses résultats financiers du premier trimestre 2022 et fait un point sur ses activités
Earnings Release Q1 2022
2022-05-05 French
Valneva lance un essai clinique évaluant son candidat vaccin contre la COVID-19 comme rappel hétérologue
Regulatory Filings
2022-05-04 French
Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine Candidate
Regulatory Filings
2022-05-04 English
VALNEVA Déclaration d’actions et de droits de vote - 30 avril 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-03 French
VALNEVA Declaration of shares and voting rights - April 30, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-05-03 English
FORM 6-K
Foreign Filer Report
2022-04-26 English
FORM 6-K
Foreign Filer Report
2022-04-19 English
Valneva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Regulatory Filings
2022-04-14 French
Valneva reçoit une autorisation conditionnelle de mise sur le marché de la MHRA au Royaume-Uni pour son vaccin inactivé contre la COVID-19
Regulatory Filings
2022-04-14 French
Valneva Receives Conditional Marketing Authorization from UK MHRA for its Inactivated COVID-19 Vaccine
Regulatory Filings
2022-04-14 English
VALNEVA Déclaration d’actions et de droits de vote - 31 mars 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-07 French
VALNEVA Declaration of shares and voting rights - March 31, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-04-07 English
FORM 6-K
Foreign Filer Report
2022-03-25 English
Valneva annonce le dépôt de son Document d’Enregistrement Universel 2021 et de son rapport annuel américain « Form 20-F »
Report Publication Announcement
2022-03-24 French
Valneva Announces Filing of 2021 Universal Registration Document and US Form 20-F
Report Publication Announcement
2022-03-24 English
ANNUAL REPORT OF FOREIGN PRIVATE ISSUER
Annual Report FY 2021
2022-03-24 English
Valneva Reports Full Year 2021 Results and Provides Corporate Updates
Earnings Release FY 2021
2022-03-24 English
Valneva publie ses résultats financiers 2021 et fait un point sur ses activités
Earnings Release FY 2021
2022-03-24 French
Document d'enregistrement universel 2021
Annual Report (ESEF) FY 2021
2022-03-23 French
FORM 6-K
Foreign Filer Report
2022-03-22 English
Valneva annonce le renouvellement des mandats des membres de son directoire
Board/Management Information
2022-03-16 French
Valneva Announces Renewal of the Term of Office of its Management Board Members
Board/Management Information
2022-03-16 English
FORM 6-K
Foreign Filer Report
2022-03-14 English
Valneva Provides Regulatory Update on its COVID-19 Vaccine Candidate
Regulatory Filings
2022-03-11 English
Valneva fait un point sur le processus réglementaire pour son candidat vaccin inactivé contre la COVID-19
Regulatory Filings
2022-03-11 French
FORM 6-K
Foreign Filer Report
2022-03-08 English
Valneva achève avec succès l'essai pivot de Phase 3 de son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-03-08 French
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Regulatory Filings
2022-03-08 English
VALNEVA Déclaration d’actions et de droits de vote - 28 février 2022
Declaration of Voting Results & Voting Rights Announcements
2022-03-04 French
VALNEVA Declaration of shares and voting rights - February 28, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-03-04 English
FORM 6-K
Foreign Filer Report
2022-03-01 English
Bahrein autorise l’utilisation d’urgence du vaccin inactivé de Valneva contre la COVID-19, VLA2001
Regulatory Filings
2022-03-01 French
Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001
Regulatory Filings
2022-03-01 English
Valneva reçoit une évaluation initiale du CHMP pour son candidat vaccin inactivé contre la COVID-19, VLA2001
Legal Proceedings Report
2022-02-25 French
Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001
Regulatory Filings
2022-02-25 English
FORM 6-K
Foreign Filer Report
2022-02-23 English
Valneva se voit accorder un financement jusqu’à £20 millions par Scottish Enterprise pour le développement de vaccins
Capital/Financing Update
2022-02-21 French
Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development
Capital/Financing Update
2022-02-21 English
SC 13G
Major Shareholding Notification
2022-02-10 English
Déclaration d’actions et de droits de vote de la société Valneva SE - Janvier 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-04 French
VALNEVA SE Declaration of shares and voting rights - January 2022
Declaration of Voting Results & Voting Rights Announcements
2022-02-04 English
FORM 6-K
Foreign Filer Report
2022-02-04 English
Valneva et Pfizer annoncent de nouvelles données positives de Phase 2 pour leur candidat vaccin contre la maladie de Lyme
Regulatory Filings
2022-02-04 French
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Regulatory Filings
2022-02-04 English
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
Earnings Release FY 2021
2022-02-03 English
Valneva publie son chiffre d’affaires et sa trésorerie pour l’exercice 2021 et présente des premiers éléments financiers pour l’exercice 2022
Earnings Release FY 2021
2022-02-03 French
FORM 6-K
Foreign Filer Report
2022-02-01 English
Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
Legal Proceedings Report
2022-01-31 English
Valneva lance un essai de Phase 3 chez les adolescents pour son candidat vaccin à injection unique contre le chikungunya
Regulatory Filings
2022-01-31 French
FORM 6-K
Foreign Filer Report
2022-01-26 English
Valneva Advances Booster Phase of Cov-Compare Trial of Its Inactivated COVID-19 Vaccine Candidate
Regulatory Filings
2022-01-25 English
Valneva lance la phase de rappel de l’étude Cov-Compare avec son candidat vaccin inactivé contre la COVID-19
Regulatory Filings
2022-01-25 French
FORM 6-K
Foreign Filer Report
2022-01-19 English
Le candidat vaccin inactivé de Valneva montre une neutralisation du variant Omicron
Earnings Release FY 2022
2022-01-19 French
Valneva’s Inactivated COVID-19 Vaccine Candidate Shown to Neutralize Omicron Variant
Environmental & Social Information
2022-01-19 English
FORM 6-K
Foreign Filer Report
2022-01-10 English
VALNEVA Déclaration d’actions et de droits de vote - 31 décembre 2021
Declaration of Voting Results & Voting Rights Announcements
2022-01-06 French
VALNEVA Declaration of shares and voting rights - December 31, 2021
Declaration of Voting Results & Voting Rights Announcements
2022-01-06 English
Valneva confirme le calendrier des essais cliniques et des demandes d'autorisation de son candidat vaccin inactivé contre la COVID-19, VLA2001
Regulatory Filings
2022-01-06 French
Valneva Confirms Clinical Trial and Regulatory Submission Timelines for its Inactivated COVID-19 Vaccine Candidate VLA2001
Regulatory Filings
2022-01-06 English